Hepatitis B virus quantification and detection of YMDD mutants in a single reaction by real-time PCR and annealing curve analysis

Antiviral Therapy

Volumn 13, Issue 4, 2008, Pages 469-480

  Shih, Yi Hsien ^a   Yeh, Shiou Hwei ^a   Chen, Pei Jer ^a,b   Chou, Wen Pin ^a   Wang, Hurng Yi ^a   Liu, Chun Jen ^a,b   Lu, Su Feng ^a   Chen, Ding Shinn ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE;

ACCURACY; ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; MELTING POINT; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSOR; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; VIRUS DETECTION; VIRUS MUTANT; VIRUS TITRATION; WILD TYPE;

EID: 84984586967     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Chen DS. From hepatitis to hepatoma: lessons from type B viral hepatitis. Science 1993; 262:369-370.
2. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337:1733-1745.
3. Chen PJ, Chen DS. Hepatitis B virus infection and hepatocellular carcinoma: molecular genetics and clinical perspectives. Semin Liver Dis 1999; 19:253-262.
4. Malik AH, Lee WM. Hepatitis B therapy: the plot thickens. Hepatology 1999; 30:579-581.
5. Ling R, Mutimer D, Ahmed M, et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996; 24:711-713.
6. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 24:714-717.
7. Bartholomeusz A, Locarnini SA. Antiviral drug resistance: clinical consequences and molecular aspects. Semin Liver Dis 2006; 26:162-170.
8. Chany M, Liang TJ. Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroenterology 2007; 132:1574-1585.
9. Pallier C, Castera L, Soulier A, et al. Dynamics of hepatitis B virus resistance to lamivudine. J Virol 2006; 80:643-653.
10. Kirishima T, Okanoue T, Daimon Y, et al. Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment. J Hepatol 2002; 37:259-265.
11. Pas SD, de Man RA, Fries E, Osterhaus AD, Niesters HG. The dynamics of mutations in the YMDD motif of the hepatitis B virus polymerase gene during and after lamivudine treatment as determined by reverse hybridization. J Clin Virol 2002; 25:63-71.
12. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30:567-572.
13. Liaw YF. Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. Antivir Chem Chemother 2001; 12:67-71.
14. Yuen MF, Kato T, Mizokami M, et al. Clinical outcome and virologic profiles of severe hepatitis B exacerbation due to YMDD mutations. J Hepatol 2003; 39:850-855.
15. Yuen MF, Yuan HJ, Sablon E, et al. Long-term follow-up study of Chinese patients with YMDD mutations: significance of hepatitis B virus genotypes and characteristics of biochemical flares. J Clin Microbiol 2004; 42:3932-3936.
16. Liaw YF, Chien RN, Yeh CT. No benefit to continue lamivudine therapy after emergence of YMDD mutations. Antivir Ther 2004; 9:257-262.
17. Liaw YF. Therapy of chronic hepatitis B: current challenges and opportunities. J Viral Hepat 2002; 9:393-399.
18. Perrillo R, Schiff E, Yoshida E, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32:129-134.
19. Lampertico P, Vigano M, Manenti E, Iavarone M, Lunghi G, Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005; 42:1414-1419.
20. Rivkin A. A review of entecavir in the treatment of chronic hepatitis B infection. Curr Med Res Opin 2005; 21:1845-1856.
21. Leemans WF, Flink HJ, Janssen HL, Niesters HG, Schalm SW, de Man RA. The effect of pegylated interferon-alpha on the treatment of lamivudine resistant chronic HBeAg positive hepatitis B virus infection. J Hepatol 2006; 44:507-511.
22. Kobayashi S, Ide T, Sata M. Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers. J Hepatol 2001; 34:584-586.
23. Lee CH, Kim SO, Byun KS, et al. Predominance of hepatitis B virus YMDD mutants is prognostic of viral DNA breakthrough. Gastroenterology 2006; 130:1144-1152.
24. Allen MI, Gauthier J, DesLauriers M, et al. Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine. J Clin Microbiol 1999; 37:3338-3347.
25. Jardi R, Buti M, Rodriguez-Frias F, et al. Rapid detection of lamivudine-resistant hepatitis B virus polymerase gene variants. J Virol Methods 1999; 83:181-187.
26. Stuyver L, Van Geyt C, De Gendt S, et al. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy. J Clin Microbiol 2000; 38:702-707.
27. Aberle SW, Kletzmayr J, Watschinger B, Schmied B, Vetter N, Puchhammer-Stockl E. Comparison of sequence analysis and the INNO-LiPA HBV DR line probe assay for detection of lamivudine-resistant hepatitis B virus strains in patients under various clinical conditions. J Clin Microbiol 2001; 39:1972-1974.
28. Whalley SA, Brown D, Teo CG, Dusheiko GM, Saunders NA. Monitoring the emergence of hepatitis B virus polymerase gene variants during lamivudine therapy using the LightCycler. J Clin Microbiol 2001; 39:1456-1459.
29. Wightman F, Walters T, Ayres A, et al. Comparison of sequence analysis and a novel discriminatory real-time PCR assay for detection and quantification of Lamivudine-resistant hepatitis B virus strains. J Clin Microbiol 2004; 42:3809-3812.
30. Punia P, Cane P, Teo CG, Saunders N. Quantitation of hepatitis B lamivudine resistant mutants by real-time amplification refractory mutation system PCR. J Hepatol 2004; 40:986-992.
31. Cane PA, Cook P, Ratcliffe D, Mutimer D, Pillay D. Use of real-time PCR and fluorimetry to detect lamivudine resistance-associated mutations in hepatitis B virus. Antimicrob Agents Chemother 1999; 43:1600-1608.
32. Bai YJ, Zhao JR, Lv GT, et al. Rapid and high throughput detection of HBV YMDD mutants with fluorescence polarization. World J Gastroenterology 2003; 9:2344-2347.
33. Jang H, Cho M, Heo J, et al. Oligonucleotide chip for detection of Lamivudine-resistant hepatitis B virus. J Clin Microbiol 2004; 42:4181-4188.
34. Lindstrom A, Odeberg J, Albert J. Pyrosequencing for detection of lamivudine-resistant hepatitis B virus. J Clin Microbiol 2004; 42:4788-4795.
35. Sablon E, Shapiro F. Advances in molecular diagnosis of HBV infection and drug resistance. Int J Med Sci 2005; 2:8-16.
36. Carman W, Thomas H, Domingo E. Viral genetic variation: hepatitis B virus as a clinical example. Lancet 1993; 341:349-353.
37. Stuyver L, De Gendt S, Van Geyt C, et al. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J Gen Virol 2000; 81:67-74.
38. Norder H, Courouce A-M, Magnius LO. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. Virology 1994; 198:489-503.
39. Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000; 118:554-559.
40. Yeh SH, Tsai CY, Kao JH, et al. Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis. J Hepatol 2004; 41:659-666.